Real-World Outcomes in the Evolving Second-Line Systemic Therapy Landscape in Hepatocellular Carcinoma: A Single-Institution Experience. (PubMed, Am J Clin Oncol) - Oct 6, 2026 - "One third of patients received second-line therapy, with patient choice and declining performance status as leading barriers. Ramucirumab's underutilization, comparable efficacy, and favorable toxicity profile make it worthy of increased consideration for second-line systemic therapy. Prospective studies are needed to elucidate factors influencing optimal second-line therapy in HCC."
Journal • Real-world evidence • Hepatocellular Cancer • Oncology • Solid Tumor
|
|
Kayeromi Gomez; Mark F deBettencourt; Nina Undevia Yedavalli
|